Alkyl Amide Pyrimidine Compounds for Tyk2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders related to IL-12, IL-23, and IFNα signaling pathways are limited in efficacy and specificity, with existing therapies often having broad immune suppression effects and potential side effects.
Innovation Solution
Development of alkyl amide-substituted pyrimidine compounds that inhibit Tyk2-mediated signal transduction, specifically targeting IL-12, IL-23, and IFNα to modulate cytokine responses, thereby treating autoimmune and inflammatory diseases with enhanced specificity and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad immune suppression therapy is used to treat autoimmune disorders, then therapeutic coverage is improved, but side effects and loss of immune function increase
Solution Approach 1:
The patent segments the immune system's cytokine signaling pathways by specifically targeting Tyk2 kinase, which mediates IL-12, IL-23, and IFNα signaling. This selective inhibition allows treatment of autoimmune disorders through specific pathway blockade rather than broad immune suppression, thereby maintaining therapeutic coverage while reducing side effects associated with non-specific immunosuppression.
2Reliability
If existing IL-12/IL-23 pathway therapies are used, then autoimmune disease treatment is improved, but specificity and reduction of immune suppression are insufficient
Solution Approach 1:
The patent employs parameter changes by developing small molecule Tyk2 inhibitors with optimized binding affinity and selectivity. The compounds feature specific molecular structures (pyrimidine cores with various substituents) that enable precise interaction with Tyk2's ATP-binding site, achieving high specificity for IL-12/IL-23/IFNα pathways while maintaining treatment efficacy for autoimmune diseases.
Data Source
AI summary
Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.